Skip to main content

Molnupiravir Dosage

Medically reviewed by Drugs.com. Last updated on Sep 10, 2024.

Applies to the following strengths: 200 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for COVID-19

For investigational use only

800 mg orally every 12 hours for 5 days

Comments:


Use: For the treatment of patients with mild to moderate COVID-19:

Renal Dose Adjustments

Renal dysfunction: No adjustment recommended

Liver Dose Adjustments

Liver dysfunction: No adjustment recommended

Precautions

US BOXED WARNINGS:
Mandatory Requirements for Administration of Molnupiravir Under EUA:

(1) Treatment of adults with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by US FDA are not accessible/clinically appropriate
(2) The prescribing health care provider should review the Fact Sheet for Patients and Caregivers with the patient or caregiver before the patient receives this drug; health care providers must provide an electronic or hard copy of the Fact Sheet for Patients and Caregivers to the patient/caregiver before the patient receives this drug and must document that the patient/caregiver was given an electronic/hard copy of the Fact Sheet for Patients and Caregivers.
(3) The prescribing health care provider must inform the patient/caregiver that:
(4) The prescribing health care provider must assess whether a female of childbearing potential is pregnant or not, if clinically indicated.
(5) Based on findings from animal reproduction studies, this drug may cause fetal harm when administered to pregnant patients; if this drug is used during pregnancy, the prescribing health care providers must counsel the patient about the known and potential benefits and the potential risk of using this drug during pregnancy, as summarized in the Fact Sheet for Patients and Caregivers.
(6) If the decision is made to use this drug during pregnancy, the prescriber must document that the known and potential benefits and the potential risk of using this drug during pregnancy, as summarized in the Fact Sheet for Patients and Caregivers, were discussed with the patient.
(7) The prescribing health care provider must document that a pregnant patient was advised of the pregnancy registry at covid-pr.pregistry.com or 1-800-616-3791.
(8) The prescribing health care provider and/or the provider's designee is/are responsible for mandatory reporting of all medication errors and serious adverse events potentially related to this drug within 7 calendar days from health care provider's awareness of the event.

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.